ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy
Source abstract
Abstract
Selective in situ activation of prodrugs or generation of bioactive drugs is an important approach to reducing the side effects of chemotherapy. Herein, a tailored ROS-activable prodrug nanomedicine (Cu-SK@DTC-PPB) was developed as the prodrug activation nanoamplifier for highly selective antitumor therapy. Cu-SK@DTC-PPB was rationally constructed by the diethyldithiocarbamate (DTC) prodrug DTC-PPB and the nanoscale coordinated framework Cu-SK based on copper and the ROS generator shikonin (SK). Cu2+, SK and DTC were kept in the inactive state in the fabricated Cu-SK@DTC-PPB. In the presence of ROS within tumors, DTC-PPB can be activated to release less cytotoxic DTC, which can rapidly chelate Cu2+ from the Cu-SK framework to synthesize highly cytotoxic Cu(DTC)2 and induce SK to release in a cascade. The released SK can generate ROS to increase the intracellular ROS level, further activating DTC-PPB to release more DTC. That is, Cu-SK@DTC-PPB can undergo a self-amplifying positive feedback loop to induce numerous bioactive Cu(DTC)2 formation and SK release triggered by a small amount of ROS within the tumor microenvironment, which endows the transformation of "less toxic-to-high toxic" and thus significantly improve its selectivity towards tumors. Therefore, this study provides a new strategy of prodrug activation for tumor therapy with high efficiency and low toxicity. STATEMENT OF SIGNIFICANCE: Owing to the striking difference in ROS level between cancer cells and normal cells, ROS-responsive prodrugs are regarded as a promising approach for tumor-specific therapy. However, the stability and responsiveness of prodrugs are hard to balance. Preferable sensitivity may cause premature activation while favorable stability may lead to incomplete prodrug activation and insufficient active drug release. This study provides a tailored ROS-responsive prodrug activation nanoamplifier with favorable stability and effective prodrug activation capacity. The nanoamplifier can undergo a self-amplifying positive feedback loop to achieve numerous bioactive drugs generation in situ under ROS triggers within the tumor microenvironment, showing the enhanced antitumor therapeutic effect. Thus, this study provides a new strategy for prodrug activation and tumor-specific therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Smart stimuli-responsive nanocarriers for the cancer therapy – nanomedicine10.1515/ntrev-2021-0067 ↗
2. Stimulus-responsive self-assembled prodrugs in cancer therapy10.1039/D2SC01003H ↗
3. Reactive oxygen species-activated self-amplifying prodrug nanoagent for tumor-specific Cu-chelate chemotherapy and cascaded photodynamic therapy10.1016/j.biomaterials.2022.121513 ↗
4. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery10.1016/j.jconrel.2010.08.027 ↗
5. Pure redox-sensitive paclitaxel-maleimide prodrug nanoparticles: endogenous albumin-induced size switching and improved antitumor efficiency10.1016/j.apsb.2020.12.001 ↗
6. Oxidative-species-selective materials for diagnostic and therapeutic applications10.1002/anie.201915833 ↗
7. Polymer prodrug-based nanoreactors activated by tumor acidity for orchestrated oxidation/chemotherapy10.1021/acs.nanolett.7b03531 ↗
8. Cancer-specific chemotherapeutic strategy based on the vitamin K3 mediated ROS regenerative feedback and visualized drug release in vivo10.1016/j.biomaterials.2018.08.065 ↗
9. Cinnamaldehyde-based poly(ester-thioacetal) to generate reactive oxygen species for fabricating reactive oxygen species-responsive nanoparticles10.1021/acs.biomac.8b01423 ↗
10. Reactive oxygen species-activatable self-amplifying Watson-Crick base pairing-inspired supramolecular nanoprodrug for tumor-specific therapy10.1016/j.biomaterials.2021.121128 ↗
11. Prodrug strategies for targeted therapy triggered by reactive oxygen species10.1039/C9MD00169G ↗
12. A tumor-specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers10.1002/adma.201702342 ↗
13. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
14. A ROS-responsive aspirin polymeric prodrug for modulation of tumor microenvironment and cancer immunotherapy10.31635/ccschem.020.202000140 ↗
15. pH/H2O2 dual-responsive chiral mesoporous silica nanorods coated with a biocompatible active targeting ligand for cancer therapy10.1021/acsami.1c08532 ↗
16. Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens
17. Old wine in new bottles: advanced drug delivery systems for disulfiram-based cancer therapy10.1016/j.jconrel.2020.01.001 ↗
18. In situ triggering antitumor efficacy of alcohol-abuse drug disulfiram through Cu-based metal-organic framework nanoparticles10.1016/j.apsb.2021.01.013 ↗
19. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL410.1038/nature25016 ↗
20. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells10.2174/138955712802762068 ↗
21. Enhanced tumor-specific disulfiram chemotherapy by In Situ Cu2+ chelation-initiated nontoxicity-to-toxicity transition10.1021/jacs.9b03503 ↗
22. Copper-enriched prussian blue nanomedicine for in situ disulfiram toxification and photothermal antitumor amplification10.1002/adma.202000542 ↗
23. Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy10.1016/j.jconrel.2021.11.041 ↗
24. A dithiocarbamate-based H2O2-responsive prodrug for combinational chemotherapy and oxidative stress amplification therapy10.1039/C9CC05438C ↗
25. Leveraging gamma-glutamyl transferase to direct cytotoxicity of copper dithiocarbamates against prostate cancer cells10.1002/anie.201807582 ↗
26. Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation10.1038/aps.2017.112 ↗
27. Synthesis, biological function and evaluation of Shikonin in cancer therapy10.1016/j.fitote.2019.03.005 ↗
28. A stimuli-responsive small-molecule metal-carrying prochelator: a novel prodrug design strategy for metal complexes10.1002/anie.202203500 ↗
29. ROS-responsive and multifunctional anti-Alzheimer prodrugs: tacrine-ibuprofen hybrids via a phenyl boronate linker10.1016/j.ejmech.2020.112997 ↗
30. Biocompatible polymeric nanoparticles degrade and release cargo in response to biologically relevant levels of hydrogen peroxide10.1021/ja303372u ↗
31. Biodegradable nanocatalyst with self-supplying fenton-like ions and H2O2 for catalytic cascade-amplified tumor therapy10.1021/acsami.1c14598 ↗
32. Pharmacological properties and derivatives of shikonin-a review in recent years10.1016/j.phrs.2019.104463 ↗
33. In situ polymerized hollow mesoporous organosilica biocatalysis nanoreactor for enhancing ROS-mediated anticancer therapy
34. Polyphenol-containing nanoparticles: synthesis, properties, and therapeutic delivery10.1002/adma.202007356 ↗
35. Fe(III)-shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis
36. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice10.1038/s41587-020-0707-9 ↗
37. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment10.1016/j.ctrv.2008.07.004 ↗